2016
Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis
Popov VB, Thompson CC, Kumar N, Ciarleglio MM, Deng Y, Laine L. Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis. Digestive Diseases And Sciences 2016, 61: 2477-2487. PMID: 27207181, DOI: 10.1007/s10620-016-4178-2.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver enzymesIntragastric balloonMarkers of NAFLDEffective short-term treatmentIntragastric balloon placementObese adult patientsNAFLD activity scoreFatty liver diseaseStudy inclusion criteriaShort-term treatmentMagnetic resonance imagingResultsNine observational studiesBackgroundIntragastric balloonsIGB therapyBalloon insertionLiver testsAdult patientsBalloon therapyObese patientsBalloon removalActivity scoreLiver diseaseHepatic steatosisBalloon placement
2008
COX-2 Selective Inhibitors in the Treatment of Osteoarthritis
Laine L, White WB, Rostom A, Hochberg M. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars In Arthritis And Rheumatism 2008, 38: 165-187. PMID: 18177922, DOI: 10.1016/j.semarthrit.2007.10.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTraditional nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsTreatment of osteoarthritisBlood pressureNonselective nonsteroidal antiinflammatory drugsCyclooxygenase-2 selective inhibitorCOX-2 selective inhibitorsClinical liver injuryHepatic side effectsSignificant renal dysfunctionCongestive heart failureSelective inhibitorAminotransferase elevationClinical hepatotoxicityGastrointestinal complicationsHypertensive patientsRenal dysfunctionUlcer complicationsCardiovascular riskSevere painGastroduodenal ulcersHeart failureLiver injuryOA patientsRandomized trials
2006
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiology And Drug Safety 2006, 15: 213-220. PMID: 16456879, DOI: 10.1002/pds.1207.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsAlanine TransaminaseAnti-Inflammatory Agents, Non-SteroidalArchivesBenzophenonesBiomarkersBromobenzenesChemical and Drug Induced Liver InjuryHumansLiverPhenylacetatesPropionatesRandomized Controlled Trials as TopicUnited StatesUnited States Food and Drug AdministrationConceptsAcute liver failureNonsteroidal anti-inflammatory drugsSerious hepatotoxicityLiver failureRisk of ALFSystematic reviewDifferent nonsteroidal anti-inflammatory drugsCommon adverse eventsHepatic enzyme elevationFlu-like symptomsDrug-induced hepatotoxicityAnti-inflammatory drugsClinical trial dataSymptomatic hepatitisALT elevationElevated transaminasesAdverse eventsEnzyme elevationDrug withdrawalHepatocellular jaundiceRare caseMedWatch systemDrug AdministrationHepatotoxicityTrial data